Barry was appointed as Cassava's executive chairman on July 17, 2024. He has served on the biopharmaceutical company's board of directors since June 2021. Barry is leading Cassava as it searches for a new CEO following former CEO Remi Barbier's resignation last week. Is Cassava Sciences stock a buy after its rebound? Why did investors like what Cassava's new executive chairman said? Despite the strong gains today, Cassava Sciences' share price is still down more than 40% year to date. Is the beaten-down bio ...

Mr. Barry succeeds Remi Barbier, the Company's Chairman, President and CEO, who resigned from the Company and the Board. Mr. Barbier will remain employed by the Company until September 13, 2024 in a nonexecutive capacity, without duties or responsibilities. "As a public company, and one dedicated to developing a drug for Alzheimer's disease, we hold ourselves to the highest standards," Mr. Barry said. "While our priority remains the development of a potentially effective treatment for Alzheimer's disease, t ...

In a public statement about Wang's indictment, Cassava didn't disclose if there had been further contact with government agencies. However, the company emphasized in this statement that Wang and the medical school where he previously worked "have had no involvement in the Company's Phase 3 clinical trials of simufilam." What does this mean for Cassava Sciences? The biotech stock is feeling the heat from an indictment of a former consultant. Cassava has revealed that some government agencies have asked for i ...

Shares of Cassava Sciences (NASDAQ:SAVA), which has an Alzheimer's drug candidate called simufilam, fell 35% on June 28 and another 13% over the weekend. This move in SAVA stock comes after a key science advisor was charged with defrauding the National Institutes of Health (NIH). We may be getting our answer. Last year, a CUNY investigation found signs that images in Wang's early papers were manipulated. This included a 2012 paper indicating simufilam "can blunt the pathological effects of beta amyloid, a p ...

AUSTIN, Texas, June 28, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), reported it has learned today that a federal grand jury returned an indictment charging Hoau-Yan Wang for allegedly defrauding the U.S. National Institutes of Health (NIH). Hoau-Yan Wang was a tenured medical professor at a public university's medical school as well as a former paid science advisor to Cassava Sciences. According to public court documents, Dr. Wang engaged in illegal behavior to defraud the government thr ...

AUSTIN, Texas, June 28, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), reported it has learned today that a federal grand jury returned an indictment charging Hoau-Yan Wang for allegedly defrauding the U.S. National Institutes of Health (NIH). Hoau-Yan Wang was a tenured medical professor at a public university's medical school as well as a former paid science advisor to Cassava Sciences. According to public court documents, Dr. Wang engaged in illegal behavior to defraud the government thr ...

This week in Cheap Seats: Stocks Under $20 segment, we're taking a look at two stocks presenting an interesting buying opportunity: Cassava Sciences Inc (NASDAQ:SAVA) and Vale SA (NYSE:VALE). A short squeeze could generate tailwinds for the shares. Short interest fell 7.7% over the most recent reporting period, but the 12.80 million shares sold short still make up 28.6% of SAVA's available float. It would take shorts more than three weeks to buy back their bearish bets, at the stock's average pace of tradin ...

After reaching an important support level, Cassava Sciences, Inc. (SAVA) could be a good stock pick from a technical perspective. SAVA recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average. A golden cross is a technical chart pattern that can signify a potential bullish breakout. It's formed from a crossover involving a security's short-term moving average breaking above a longer-term moving average, with the most common ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 000-29959 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 91-191133 ...

EXHIBIT 99.1 Cassava Sciences Reports Full-year 2023 Financial Results and Corporate Updates AUSTIN, Texas, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer's disease, today reported financial and operating results for the full year ended December 31, 2023 and presented corporate updates. "I see Alzheimer's disease as one of the last great frontiers in medicine," said Remi Barbier, President & CEO. "It's clear to me these patients need new ...